Dynamic and modern: Bringing the ethics of phase I trials up to date

被引：1
作者：
Camidge, D. Ross [1 ]
Eckhardt, S. Gail [1 ]
Gore, Lia [1 ]
机构：
[1] Colorado Canc Ctr Aurora, Dev Therapeut Program, Denver, CO USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 32期
关键词：
D O I：
10.1200/JCO.2006.09.1207
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：5178 / 5179
页数：2
相关论文
共 5 条
[1]   Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types [J].
Baselga, J ;
Rischin, D ;
Ranson, M ;
Calvert, H ;
Raymond, E ;
Kieback, DG ;
Kaye, SB ;
Gianni, L ;
Harris, A ;
Bjork, T ;
Averbuch, SD ;
Feyereislova, A ;
Swaisland, H ;
Rojo, F ;
Albanell, J .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) :4292-4302
[2]   Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. [J].
Druker, BJ ;
Talpaz, M ;
Resta, DJ ;
Peng, B ;
Buchdunger, E ;
Ford, JM ;
Lydon, NB ;
Kantarjian, H ;
Capdeville, R ;
Ohno-Jones, S ;
Sawyers, CL .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1031-1037
[3]   Rethinking risk-benefit assessment for phase I cancer trials [J].
Joffe, Steven ;
Miller, Franklin G. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (19) :2987-2990
[4]   Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials [J].
Roberts, TG ;
Goulart, BH ;
Squitieri, L ;
Stallings, SC ;
Halpern, EF ;
Chabner, BA ;
Gazelle, GS ;
Finkelstein, SN ;
Clark, JW .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (17) :2130-2140
[5]   RESPONSE RATES, DURATION OF RESPONSE, AND DOSE-RESPONSE EFFECTS IN PHASE-I STUDIES OF ANTINEOPLASTICS [J].
VONHOFF, DD ;
TURNER, J .
INVESTIGATIONAL NEW DRUGS, 1991, 9 (01) :115-122
1